PT3234597T - Proteínas da via de sinalização wnt e suas utilizações no diagnóstico e tratamento de distúrbios de hipopigmentação - Google Patents
Proteínas da via de sinalização wnt e suas utilizações no diagnóstico e tratamento de distúrbios de hipopigmentaçãoInfo
- Publication number
- PT3234597T PT3234597T PT158133678T PT15813367T PT3234597T PT 3234597 T PT3234597 T PT 3234597T PT 158133678 T PT158133678 T PT 158133678T PT 15813367 T PT15813367 T PT 15813367T PT 3234597 T PT3234597 T PT 3234597T
- Authority
- PT
- Portugal
- Prior art keywords
- diagnostic
- proteins
- treatment
- signaling pathway
- wnt signaling
- Prior art date
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/14—Alkali metal chlorides; Alkaline earth metal chlorides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
- G01N33/5023—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects on expression patterns
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/118—Prognosis of disease development
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/136—Screening for pharmacological compounds
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/20—Dermatological disorders
- G01N2800/207—Pigmentation disorders
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/56—Staging of a disease; Further complications associated with the disease
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP14307089 | 2014-12-18 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PT3234597T true PT3234597T (pt) | 2022-02-15 |
Family
ID=52396377
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PT158133678T PT3234597T (pt) | 2014-12-18 | 2015-12-16 | Proteínas da via de sinalização wnt e suas utilizações no diagnóstico e tratamento de distúrbios de hipopigmentação |
Country Status (7)
| Country | Link |
|---|---|
| US (2) | US10983134B2 (pt) |
| EP (1) | EP3234597B1 (pt) |
| DK (1) | DK3234597T3 (pt) |
| ES (1) | ES2905438T3 (pt) |
| PL (1) | PL3234597T3 (pt) |
| PT (1) | PT3234597T (pt) |
| WO (1) | WO2016097035A1 (pt) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2905438T3 (es) * | 2014-12-18 | 2022-04-08 | Inst Nat Sante Rech Med | Proteínas de la vía de señalización de WNT y usos de las mismas en el diagnóstico y tratamiento de trastornos de hipopigmentación |
| US20230338430A1 (en) * | 2021-01-16 | 2023-10-26 | Haikou Renshu Dermatology Clinic Co., Ltd | Technical method for treating vitiligo through hair follicle melanocyte stem cell transplantation |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7368131B2 (en) * | 2003-02-27 | 2008-05-06 | Supernatural Health, Inc. | Method and composition for treating hypopigmentation of the hair and skin |
| DE202004013006U1 (de) | 2004-07-15 | 2004-11-04 | Otto Sauer Achsenfabrik Keilberg | Bremseinrichtung mit Bremssattelbefestigung |
| WO2006078886A2 (en) * | 2005-01-18 | 2006-07-27 | Irm Llc | Compounds and compositions as wnt signaling pathway modulators |
| KR20110130282A (ko) | 2010-05-27 | 2011-12-05 | 아주대학교산학협력단 | Ｗｉｆ-1 조절을 통한 색소 질환 치료용 조성물 |
| KR102031161B1 (ko) * | 2011-10-18 | 2019-10-14 | (주)아모레퍼시픽 | 피부 미백 물질 스크리닝 시스템 |
| KR20130073069A (ko) | 2011-12-23 | 2013-07-03 | 현대모비스 주식회사 | 오디오 이상 유무 자가 진단 가능한 음원 재생 장치 및 그 방법 |
| ES2895628T3 (es) * | 2014-12-18 | 2022-02-22 | Inst Nat Sante Rech Med | Inhibidores de GSK3B en el tratamiento de trastornos de hipopigmentación |
| ES2905438T3 (es) * | 2014-12-18 | 2022-04-08 | Inst Nat Sante Rech Med | Proteínas de la vía de señalización de WNT y usos de las mismas en el diagnóstico y tratamiento de trastornos de hipopigmentación |
-
2015
- 2015-12-16 ES ES15813367T patent/ES2905438T3/es active Active
- 2015-12-16 DK DK15813367.8T patent/DK3234597T3/da active
- 2015-12-16 US US15/536,332 patent/US10983134B2/en active Active
- 2015-12-16 PT PT158133678T patent/PT3234597T/pt unknown
- 2015-12-16 WO PCT/EP2015/080066 patent/WO2016097035A1/en active Application Filing
- 2015-12-16 EP EP15813367.8A patent/EP3234597B1/en active Active
- 2015-12-16 PL PL15813367T patent/PL3234597T3/pl unknown
-
2020
- 2020-12-09 US US17/116,429 patent/US11650214B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| US11650214B2 (en) | 2023-05-16 |
| US20210190800A1 (en) | 2021-06-24 |
| WO2016097035A9 (en) | 2017-08-24 |
| ES2905438T3 (es) | 2022-04-08 |
| US10983134B2 (en) | 2021-04-20 |
| EP3234597B1 (en) | 2021-11-10 |
| DK3234597T3 (da) | 2022-02-07 |
| US20180180631A1 (en) | 2018-06-28 |
| EP3234597A1 (en) | 2017-10-25 |
| WO2016097035A1 (en) | 2016-06-23 |
| PL3234597T3 (pl) | 2022-03-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL281793A (en) | Use of cannabinoids in the treatment of epilepsy | |
| PL3235830T3 (pl) | Kompleks białkowy interleukiny 15 i jego zastosowanie | |
| GB201519858D0 (en) | Therapeutic combinations comprising anti-CD73 antibodies and uses thereof | |
| PL3157512T3 (pl) | Zastosowanie kannabidioli w leczeniu padaczki | |
| GB201411496D0 (en) | Use of 7-Oh-Cannabidiol (7-Oh-CBD) and/or 7-Oh-Cannabidvarin (7-Oh-CBDV) in the treatment of epilepsy | |
| IL249580A0 (en) | Methods for anesthetizing nerve tissue in the trigeminal nerve pathway and their medical uses | |
| PL3277280T3 (pl) | Izomiosmina do zastosowania w leczeniu chorób autoimmunologicznych | |
| ZA201704726B (en) | Peptides and their use in the treatment of skin | |
| IL251904B (en) | Epilimod for use in the treatment of melanoma | |
| GB201515986D0 (en) | Use of cannabinoids in the treatment of mental disorders | |
| HUE062784T2 (hu) | Indolinon vegyületek és alkalmazásuk fibrotikus betegségek kezelésében | |
| HUE039750T2 (hu) | Hidroxi-buspiron mozgászavarok kezelésére | |
| PT3177599T (pt) | Análogos fumarato e utilizações dos mesmos no tratamento de uma doença autoimune ou uma doença inflamatória | |
| GB201423272D0 (en) | The combination for anti-wrinkle and soothing the skin | |
| GB201404372D0 (en) | Assay and treatment | |
| SG11201704486TA (en) | Improvements in and relating to the treatment of matrices and/or the contents of matrices | |
| GB201500500D0 (en) | Biological materials and therapeutic uses thereof | |
| HK1217913A1 (zh) | 阿地米屈在治療上皮功能障礙中的用途 | |
| HK1209363A1 (en) | Use of lactobacillus crispatus in the treatment or prevention of rheumatoid arthritis or related diseases | |
| PL3135337T3 (pl) | Urządzenie do relaksu i odnowy ciała | |
| PT3234597T (pt) | Proteínas da via de sinalização wnt e suas utilizações no diagnóstico e tratamento de distúrbios de hipopigmentação | |
| HK1244821A1 (zh) | 用於治療和診斷1型糖尿病中使用的肽 | |
| IL251605A0 (en) | Use of protein in predicting intracorporeal phenomena | |
| GB201423270D0 (en) | The combination for soothing and repair of the skin | |
| GB201411616D0 (en) | Diagnosis and treatment of neurodegenerative disorders |